Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy

Attention-Deficit/Hyperactivity Disorder (ADHD) is a psychiatric disorder characterized by 3
main symptoms: inattention, hyperactivity and impulsivity. This study will assess the safety
and tolerability of SPD485 while attempting to establish the appropriate starting dose for
subjects previously on an existing long-acting methylphenidate product.

Inclusion Criteria:

- Subject must have a primary diagnosis of ADHD

- Subject must be adequately controlled on a stable dose of one of the following
medications for a 30 day period: Ritalin LA(r), Concerta(r), or Metadate DC(r), not
to exceed 54 mg per day

- Females of childbearing potential must have a negative serum beta Human Chorionic
Gonadotropin pregnancy test

Exclusion Criteria:

- A history of mental retardation that would indicate that the subject is not
functioning at an age appropriate level intellectually

- A recent history of suspected substance abuse or dependence disorder

- Subject is taking Strattera

- Clinical signs and symptoms of skin irritation or hyper/hypopigmentation at the
potential application sites